These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35279885)

  • 1. Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis.
    Avallone G; Cariti C; Dapavo P; Ortoncelli M; Conforto L; Mastorino L; Roccuzzo G; Cavallo F; Rubatto M; Quaglino P; Ribero S
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e574-e576. PubMed ID: 35279885
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
    Okubo Y; Mabuchi T; Iwatsuki K; Elmaraghy H; Torisu-Itakura H; Morisaki Y; Nakajo K
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):325-332. PubMed ID: 30317671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis.
    Mastorino L; Cariti C; Susca S; Siliquini N; Verrone A; Stroppiana E; Ortoncelli M; Dapavo P; Quaglino P; Ribero S
    Exp Dermatol; 2023 Sep; 32(9):1591-1594. PubMed ID: 37395012
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series.
    Lo Y; Tsai TF
    Br J Dermatol; 2019 Nov; 181(5):1106-1107. PubMed ID: 31145806
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis.
    Egeberg A; Bryld LE; Skov L
    J Am Acad Dermatol; 2019 Jul; 81(1):173-178. PubMed ID: 30914343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
    Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
    J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice.
    Herrera-Acosta E; Garriga-Martina GG; Suárez-Pérez JA; Martínez-García EA; Herrera-Ceballos E
    Dermatol Ther; 2020 May; 33(3):e13313. PubMed ID: 32181962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice.
    Reymundo A; Armesto S; Rodríguez L; Baniandrés O; Sahuquillo-Torralba A; Torres T; de la Cueva P; Llamas-Velasco M; Daudén E
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1480-e1482. PubMed ID: 37471473
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.
    Saeki H; Nakagawa H; Ishii T; Morisaki Y; Aoki T; Berclaz PY; Heffernan M
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1148-55. PubMed ID: 25355284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Controlled Ixekizumab Vs Secukinumab Trial to Study the Impact on Sexual Activity in Adult Patients with Genital Psoriasis.
    AlMutairi N; Eassa BI
    Expert Opin Biol Ther; 2021 Feb; 21(2):297-298. PubMed ID: 33115285
    [No Abstract]   [Full Text] [Related]  

  • 12. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab.
    Warren RB; Brnabic A; Saure D; Langley RG; See K; Wu JJ; Schacht A; Mallbris L; Nast A
    Br J Dermatol; 2018 May; 178(5):1064-1071. PubMed ID: 29171861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice.
    Caldarola G; Mariani M; Pirro F; Nicolotti N; Burlando M; Calabrese L; Parodi A; Peris K; De Simone C
    Expert Opin Biol Ther; 2021 Feb; 21(2):279-286. PubMed ID: 33170052
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings.
    Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour TL; Lew CR; Zimmerman NM; Atiya B; Murage MJ
    J Am Acad Dermatol; 2022 Mar; 86(3):581-589. PubMed ID: 34252464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
    Blauvelt A; Shi N; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Zhu B; Murage MJ
    J Am Acad Dermatol; 2020 Apr; 82(4):927-935. PubMed ID: 31712178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients.
    Cariti C; Dapavo P; Mastorino L; Ortoncelli M; Siliquini N; Merli M; Avallone G; Giordano S; Fabrizio R; Susca S; Verrone A; Stroppiana E; Quaglino P; Ribero S
    J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):e233-e235. PubMed ID: 34672026
    [No Abstract]   [Full Text] [Related]  

  • 17. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
    Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
    Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report.
    Dastoli S; Iannone LF; Bennardo L; Silvestri M; Palleria C; Nisticò SP; De Sarro G; Russo E
    Curr Drug Saf; 2020; 15(1):69-72. PubMed ID: 31362662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Family history of psoriasis: a novel protective factor for therapy switch in patients treated with Secukinumab or Ixekizumab.
    Manzo Margiotta F; Michelucci A; Panduri S; Tonini A; Davini G; Romanelli M; Morganti R; Dini V
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e454-e456. PubMed ID: 35048437
    [No Abstract]   [Full Text] [Related]  

  • 20. Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature.
    Liu LC; Jin XH; Sun C; Xia JX
    Dermatol Ther; 2021 Mar; 34(2):e14825. PubMed ID: 33527631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.